Rezafungin Awarded Promising Innovation Medicine (PIM) Designation by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for the Treatment of Invasive Candidiasis
Retrieved on:
Thursday, March 3, 2022
Mundipharma and Cidara Therapeutics, Inc. (NASDAQ: CDTX) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has granted rezafungin Promising Innovative Medicine (PIM) designation for the treatment of invasive candidiasis.
Key Points:
- Mundipharma and Cidara Therapeutics, Inc. (NASDAQ: CDTX) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has granted rezafungin Promising Innovative Medicine (PIM) designation for the treatment of invasive candidiasis.
- A PIM designation is a pre-requisite for application to the UKs Early Access to Medicines Scheme (EAMS).
- This scheme aims to give patients with life threatening or seriously debilitating conditions such as invasive candidiasis, access to medicines that do not yet have a marketing authorisation.
- Rezafungin, as a next generation echinocandin, has the potential to help critically ill, vulnerable patients battling invasive Candida infections.